---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-22-000029"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:49:11.779512+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exelixis files new patent infringement suit against MSN over generic CABOMETYX

## Summary
- Filed complaint in Delaware asserting infringement of three new patents (11,091,439; 11,091,440; 11,098,015) related to cabozantinib.
- MSN amended its ANDA for generic CABOMETYX tablets (20/40/60 mg); Exelixis seeks injunction and approval date no earlier than patent expiration (latest Jan 15, 2030).
- This new case is separate from the 2019/2020 MSN ANDA Actions, which are scheduled for trial in May 2022.
- Exelixis also seeks order that FDA approval of MSN's ANDA be delayed until after patent expirations.

## SEC filing metadata
- accession: 0000939767-22-000029
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976722000029/0000939767-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976722000029/exel-20220223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-22-000029
- JSON: https://secwatch.observer/filing/0000939767-22-000029.json
- Plain text: https://secwatch.observer/filing/0000939767-22-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.